90272-83-6

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-7-METHYL-QUINAZOLINE is used as a key intermediate in the synthesis of pharmaceutical drugs for its potential therapeutic applications. Its unique chemical structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
4-CHLORO-7-METHYL-QUINAZOLINE is used as a building block in the synthesis of agrochemicals, contributing to the development of novel pesticides and herbicides with enhanced selectivity and reduced environmental impact.
Used in Medicinal Chemistry Research:
4-CHLORO-7-METHYL-QUINAZOLINE is used as a research compound for exploring its biological activities, such as anti-cancer and anti-inflammatory properties. Its study aids in understanding the structure-activity relationship and the development of more effective therapeutic agents.
Used in Drug Discovery:
4-CHLORO-7-METHYL-QUINAZOLINE is used as a starting material in drug discovery processes, enabling the design and synthesis of new chemical entities with potential therapeutic benefits. Its versatile chemical properties facilitate the creation of diverse drug candidates for various diseases and conditions.

InChI:InChI=1/C9H7ClN2/c1-6-2-3-7-8(4-6)11-5-12-9(7)10/h2-5H,1H3

Upstream product

• 2305-36-4 4-methylanthranilic acid 
• 75844-40-5 7-methyl-quinazolin-4(3H)-one 

Downstream Products

• 234098-35-2 7-Bromomethyl-4-chloroquinazoline 

Relevant academic research and scientific papers

Design, Synthesis and Bioevaluation of Two Series of 3-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones and N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines

Two series of 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones and N-(1-benzylpiperidin-4-yl)quinazolin-4-amines were designed initially as potential acetylcholine esterase inhibitors. Biological evaluation demonstrated that N-(1-benzylpiperidin-4-yl)quinazolin-4-amines significantly inhibited AChE activity. Especially, two compounds of them were found to be the most potent with relative AChE inhibition percentages of 87 percent in comparison to donepezil. The docking studies with AChE showed similar interactions between donepezil and four derivatives. N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines also exhibited significant DPPH scavenging effects. The two series of compound also exerted moderate to good cytotoxicity against three human cancer cell lines, including SW620 (human colon cancer), PC-3 (prostate cancer), and NCI?H23 (lung cancer), with 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one being the most cytotoxic agent. 3-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one significantly induced early apoptosis and arrested the SW620 cells at G2/M phase. From this study, two compounds of N-(1-benzylpiperidin-4-yl)quinazolin-4-amines could serve as new leads for further design and AChE inhibitors, while 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one could serve as a new lead for the design and development of more potent anticancer agents.

IDENTIFICATION AND USE OF ERK5 INHIBITORS

The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

SYNTHETIC PROCESS

The present invention provides a process for preparing compounds of formula (IV), or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER

Substituted oxoazaheterocyclyl compounds

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..